Day: June 26, 2023

Posted on

MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa

MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa

  • First placebo-controlled randomized trial in HS to report positive topline results using HiSCR75 as the primary endpoint
  • Primary endpoint HiSCR75 met with 29 percentage points (ppt) delta vs placebo (p=0.0002) at week 12, setting a new bar in HS
  • HiSCR50 met with 38 ppt delta vs placebo (p<0.0001), greater delta than observed for any other molecules
  • Other secondary endpoints also reached statistical significance with clinically meaningful improvements at week 12, including HiSCR90, IHS4 and various patient reported outcomes
  • Safety results of sonelokimab consistent with previously reported studies with no new observed safety signals
  • These topline data will be discussed on Monday 26th June, at 2pm CEST/8am EDT, via webcast (registration link below)

ZUG, Switzerland, June 25, 2023 – MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced positive top-line results from its global Phase 2 MIRA trial evaluating the efficacy and safety of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS).

The MIRA trial (M1095-HS-201), which recruited 234 patients, is the first randomized, double-blind, placebo-controlled trial to use Hidradenitis Suppurativa Clinical Response (HiSCR) 75 as its primary endpoint, a higher measure of clinical response versus the HiSCR50 measure used in other clinical trials, therefore representing a landmark milestone in HS clinical development.

The trial met its primary endpoint with a significantly greater proportion of patients treated with both sonelokimab 120mg and 240mg achieving HiSCR75 compared to those on placebo at week 12. The primary analysis was based on the most stringent type of analysis for such trials, intent-to-treat non-responder imputation (ITT-NRI). Both doses performed similarly, with the 120mg dose providing the highest delta on HiSCR75 and HiSCR50. The 120mg dose achieved a 29 ppt delta to placebo on HiSCR75 (p=0.0002) and a 38ppt delta to placebo on HiSCR50 (p<0.0001). The results suggest that, as early as week 12, the Nanobody® sonelokimab, relative to placebo, reaches the highest clinical activity among all other therapies tested in similarly stringent pivotal-like trials.

In addition, other clinically relevant secondary endpoints, such as HiSCR90, improvements in International Hidradenitis Suppurativa Severity Score System (IHS) 4, abscess/nodule and draining tunnel counts as well as patient reported pain and quality of life outcomes also reached statistical significance at week 12. The high performance of the Nanobody® at 120mg, the dose found to be optimal in psoriasis, demonstrates the advantage of using a smaller biologic with albumin-binding capacity to inhibit IL-17A and IL-17F for the treatment of inflammatory diseases.

The safety profile of sonelokimab was consistent with previously reported studies with no new safety signals observed. Overall, sonelokimab continues to show a favorable safety profile, in line with the known profile of IL-17 inhibitors.

Jorge Santos da Silva, PhD, Founder and Chief Executive Officer at MoonLake, said: “As part of our efforts to elevate outcomes for patients, we set an ambitious goal for our Nanobody® sonelokimab to ‘meet or beat’ the best results shown in pivotal-like trials of competitors. We have achieved our ‘beat’ goal with the positive outcome of the Phase 2 MIRA trial. In doing so, we have raised the bar for what can be accomplished for HS and these positive topline data provide us with even greater confidence as we look forward to our next steps and our aspiration to become a leader in the inflammation and immunology space.”

Kristian Reich, MD, PhD, Founder and Chief Scientific Officer at MoonLake, commented: “The positive topline results from the MIRA trial establish a new era in the treatment of chronic inflammatory diseases, as our Nanobody® sonelokimab indicates a new bar versus what was achieved previously with monoclonal antibodies. Importantly, the results confirm the advantage of the Nanobody’s smaller size versus traditional antibodies in the treatment of diseases in which high-level improvements depend on optimal tissue penetration such as hidradenitis suppurativa and likely psoriatic arthritis. The data also validate sonelokimab’s unique mode of action to efficiently inhibit IL-17F in addition to IL-17A. The positive outcome of the MIRA trial would not have been possible without the support and participation of the patients and investigators to whom we are grateful.”

Alexa B. Kimball, MD, MPH, lead investigator of the MIRA trial, investigator at Beth Israel Deaconess Medical Center, Massachusetts, US, and Professor of Dermatology at Harvard Medical School, added: “Hidradenitis suppurativa is a chronic, inflammatory, recurrent, and debilitating skin disease that has profound and wide-ranging impacts across many aspects of patient’s lives. As a physician, I see tremendous need for new treatment options for people living with HS, particularly for treatments to reach high thresholds of response in clinical trials (e.g., HiSCR75 and beyond). The positive high clinical responses observed with sonelokimab in the Phase 2 MIRA trial are encouraging, demonstrating its promise as a potential future treatment option.”

These topline data will be discussed on Monday June 26, 2023 at 2pm CEST/8am EDT before the Nasdaq market opens, via webcast at:

https://onlinexperiences.com/Launch/QReg/ShowUUID=AF1A77F1-F560-4D58-AE3B-00698698C741&LangLocaleID=1033&GroupID=Onyx

A replay of the webcast and the presentation document will be made available at https://ir.moonlaketx.com.

The MIRA trial proceeds to week 24, with a 4-week safety follow-up. Important data is being collected regarding longer-term efficacy and safety of sonelokimab, as well as results from switching to sonelokimab from the placebo and the adalimumab arms. Full results from the MIRA trial will be submitted for publication in a peer-reviewed medical journal and for presentation at an upcoming scientific meeting.

Sonelokimab has already been successfully assessed in a randomized, placebo-controlled, Phase 2b trial (NCT03384745) in 313 patients with moderate-to-severe plaque-type psoriasis in which it demonstrated a rapid and durable skin clearance (PASI100) with no unexpected safety findings.

Sonelokimab is currently being evaluated in a Phase 2 trial (NCT05640245), ‘ARGO’, in patients with active psoriatic arthritis with the primary end-point readout expected in Q4 this year.

Sonelokimab is not yet approved for use in any indication.

About the MIRA trial

The MIRA trial (M1095-HS-201) is a global, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of the Nanobody® sonelokimab, administered subcutaneously, in the treatment of adult patients with active moderate-to-severe hidradenitis suppurativa. The trial recruited 234 patients, with the aim to evaluate two different doses of sonelokimab (120mg and 240mg) with placebo control and adalimumab as an active reference arm. The primary endpoint of the trial is the percentage of participants achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75), defined as a ≥75% reduction in total abscess and inflammatory nodule (AN) count with no increase in abscess or draining tunnel count relative to baseline. The trial also evaluated a number of secondary endpoints, including the proportion of patients achieving HiSCR50, the change from baseline in International Hidradenitis Suppurativa Severity Score System (IHS4), the proportion of patients achieving a Dermatology Life Quality Index (DLQI) total score of ≤5, and the proportion of patients achieving at least 30% reduction from baseline in Numerical Rating Scale (NRS30) in the Patient’s Global Assessment of Skin Pain (PGA Skin Pain). Further details are available at: https://www.clinicaltrials.gov/ct2/show/NCT05322473 .

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, a novel investigational Nanobody® for the treatment of inflammatory disease, to revolutionize outcomes for patients. Sonelokimab inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation. The company’s focus is on inflammatory diseases with a major unmet need, including hidradenitis suppurativa and psoriatic arthritis – conditions affecting millions of people worldwide with a large need for improved treatment options. MoonLake was founded in 2021 and is headquartered in Zug, Switzerland. Further information is available at www.moonlaketx.com.

About Nanobodies®

Nanobodies® represent a new generation of antibody-derived targeted therapies. They consist of one or more domains based on the small antigen-binding variable regions of heavy-chain-only antibodies (VHH). Nanobodies® have a number of potential advantages over traditional antibodies, including their small size, enhanced tissue penetration, resistance to temperature changes, ease of manufacturing, and their ability to be designed into multivalent therapeutic molecules with bespoke target combinations.

The terms Nanobody® and Nanobodies® are trademarks of Ablynx, a Sanofi company.

About Sonelokimab

Sonelokimab (M1095) is an investigational ~40 kDa humanized Nanobody® consisting of three VHH domains covalently linked by flexible glycine-serine spacers. With two domains, sonelokimab selectively binds with high affinity to IL-17A and IL-17F, thereby inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers. A third central domain binds to human albumin, facilitating further enrichment of sonelokimab at sites of inflammatory edema.

Sonelokimab has been assessed in a randomized, placebo-controlled Phase 2b study in 313 patients with moderate-to-severe plaque-type psoriasis. Sonelokimab demonstrated a rapid and durable clinical response (Investigator’s Global Assessment Score 0 or 1, Psoriasis Area and Severity Index 90/100) in patients with moderate-to-severe plaque-type psoriasis. Sonelokimab was generally well tolerated, with a safety profile similar to the active control, secukinumab (Papp KA, et al. Lancet. 2021; 397:1564-1575).

In an earlier Phase 1 study in patients with moderate-to-severe plaque-type psoriasis, sonelokimab has been shown to decrease (to normal skin levels) the cutaneous gene expression of pro-inflammatory cytokines and chemokines (Svecova D. J Am Acad Dermatol. 2019;81:196–203). Currently, a global phase 2 trial in psoriatic arthritis (NCT05640245, M1095-PSA-201, “ARGO”) including multiple arms and over 200 patients is ongoing (announced on Dec 14, 2022).

About Hidradenitis Suppurativa

Hidradenitis suppurativa is a severely debilitating chronic skin condition resulting in irreversible tissue destruction. HS manifests as painful inflammatory skin lesions, typically around the armpits, groin, and buttocks. Over time, uncontrolled and inadequately treated inflammation can result in irreversible tissue destruction and scarring. The disease affects 0.05–4.1% of the global population, with three times more females affected than males. Onset typically occurs in early adulthood and HS has a profound negative impact on quality of life, with a higher morbidity than other dermatologic conditions. There is increasing scientific evidence to support IL-17A- and IL-17F-mediated inflammation as a key driver of the pathogenesis of HS, with other identified risk factors including genetics, cigarette smoking, and obesity.

Cautionary Statement Regarding Forward Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding MoonLake’s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: plans for clinical trials and research and development programs; and the anticipated timing of the results from those trials, including completing the MIRA trial; and the efficacy of our products, if approved, including in relation to other products. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that such statement is not forward looking.

Forward-looking statements are based on current expectations and assumptions that, while considered reasonable by MoonLake and its management, as the case may be, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with MoonLake’s business in general and limited operating history, difficulty enrolling patients in clinical trials, and reliance on third parties to conduct and support its clinical trials, and the other risks described in or incorporated by reference into MoonLake’s Annual Report on Form 10-K for the year ended December 31, 2022 and subsequent filings with the Securities and Exchange Commission.

Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. MoonLake does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or in the events, conditions or circumstances on which any such statement is based.

MoonLake Immunotherapeutics Investors
Matthias Bodenstedt, CFO
info@moonlaketx.com

MoonLake Immunotherapeutics Media
Patricia Sousa
media@moonlaketx.com

Consilium Strategic Communications
Mary-Jane Elliott, Namrata Taak, Genevieve Wilson
Tel: +44 (0) 20 3709 5700
media@moonlaketx.com
MoonLake@consilium-comms.com

GlobeNewswire Distribution ID 1000826885

Posted on

Swiss National Council President’s Vietnam visit aims to promote bilateral ties: diplomat

President of the Swiss National Council Martin Candinas’s official visit to Vietnam from June 27-30 is to strengthen the good cooperation between the two countries, and consolidate the good relationship between their two legislative bodies, Swiss Ambassador Thomas Gass told the Vietnam News Agency on the threshold of the visit.

The trip will help Martin Candinas and the Swiss National Council delegation understand more about cooperation opportunities in the rapidly booming economic development of Vietnam, and promote discussions relating to the signing of a free trade agreement between Vietnam and the European Free Trade Association (EFTA) so as to promote bilateral trade-investment cooperation in the coming time.

According to the diplomat, EFTA is an intergovernmental organisation established to promote free trade and economic integration for the benefit of four member countries: Iceland, Liechtenstein, Norway, and Switzerland. These four countries are not included in the European Union-Vietnam Free Trade Agreement (EVFTA).

Like the Vietnamese National Assembly, the Swiss National Council also has the role of overseeing the activities of state administrative agencies. And during his visit to Vietnam, President Martin Candinas will supervise the management and implementation of a technical assistance package worth 70 million CHF (78.1 million USD) for Vietnam from the Swiss Government for the 2021 – 2024 period, focusing on the fields of environmental protection and economic reform; and other Swiss projects in Vietnam.

Regarding the bilateral relations, Thomas Gass said that the relationship has developed strongly over the past 52 years, not only in politics and multilateral cooperation, but also in economic cooperation, technical assistance, trade and investment, scientific research, culture, tourism, and people-to-people exchanges.

Switzerland always attaches importance to its friendship and cooperation with Vietnam, and at the same time identifies Vietnam as an increasingly important economic partner and the two sides have a lot of room for cooperation, he said.

“We look forward to accelerating the negotiation process of the Vietnam-EFTA; at the same time, strengthen bilateral cooperation to implement the Sustainable Development Goals in the fields of finance-banking, supporting the business-start-up community, science-technology, education-training, tourism, climate change response and people-to-people exchanges. These are also the topics that we want to discuss with Vietnamese leaders during the visit of President Martin Candinas,” said the diplomat. Regular high-level exchanges between the two countries have paved the way for ever-increasing trade and investment relations.

The diplomat went on to say that Vietnam has great potential in innovation and digital transformation, especially when it has a very dynamic and creative young population. And if it takes advantage of this strength, Vietnam will certainly continue to develop with great strides.

In the context that Vietnam is implementing the Socio-Economic Development Strategy for the 2021-2030 period with science and technology playing a key role and Switzerland has strengths in the fields of innovation and transformation, Switzerland to further strengthen cooperation between the two countries in science and technology, education and training, towards establishing a partnership framework on innovation, he stated.

Switzerland will welcome Vietnamese delegations to exchange specific cooperation, including cooperation between leading universities of the two nations.

Switzerland will use new and digital technologies, for example in financial technology applications, using e-commerce platforms, or management of public assets; and support innovative solutions to improve resilience to climate change and urban planning towards sustainable development in cities for its activities in Vietnam, he added./.

Source: Vietnam News Agency

Posted on

Exchange rate forecast to remain stable in second half of 2023

The period of strong volatility of the US dollar has ended, and the USD/VND exchange rate in the last six months of 2023 will remain stable, experts have forecast.

According to experts of Yuanta Vietnam Securities Company, the USD/VND exchange rate from the beginning of 2023 fluctuated around a range of +/- 1.9% at 23,240 – 23,630 VND per dollar, much more stable than in 2022 when the rate sometimes peaked at 24,692 VND per dollar, up 4.2% against the State Bank of Vietnam (SBV)’s reference exchange rate.

As of the beginning of June, the USD/VND exchange rate decreased by about 0.52% compared to the start of 2023 thanks to the abundant supply of foreign currency from the trade balance surplus, disbursed FDI inflows, international tourism recovery and the weakening of the dollar.

According to the experts, there are a number of factors that positively support the exchange rate in the second half of this year.

First, Vietnam’s foreign exchange reserves have grown again. After strong fluctuations in the monetary market in 2022, the nation’s foreign exchange reserves at the end of 2022 reached about 90 billion USD. In the first five months of 2023, the SBV bought about 6 billion USD to add to foreign reserves.

Second, the country’s trade balance recorded a surplus in the first five months of this year. Although import-export turnover in the first five months of 2023 was low, the trade balance maintained a trade surplus of 9.8 billion USD, a sharp increase compared to 2021 and 2022.

Third, Vietnam’s tourism industry is recovering. After three years of being affected by the COVID-19 pandemic, the number of tourists to Vietnam in the first five months of 2023 rose 13 times compared to the same period in 2022 and equivalent to 63% compared to before the pandemic in 2019.

International tourists will recover faster in the near future, especially from China in the summer and early fourth quarter of 2023. This will also be a significant source of foreign currency for the country.

Fourth, FDI has shown more positive signals. Although accumulated FDI in the first five months of 2023 decreased slightly compared to the same period last year, the data in April and May 2023 showed more positive signals thanks to the gradually improving macro factors. Though more observations are needed, Yuanta holds a positive view on FDI inflows in the medium and long term, adding this is also a significant supporting factor for the dollar flowing into Vi?t Nam.

Fifth, the US Federal Reserve (Fed) may soon stop raising interest rates. Yuanta said though it is likely that the Fed will raise interest rates at least one more time this year, the tightening of interest rates has been loosened more and the period when the dollar was anchored at a high level as 2022 ended.

Sixth, Vietnam’s remittances are expected to continue to increase. In addition to the amount of remittances sent back to relatives that remains stable, Yuanta’s analysts expect the amount of remittances sent to invest in Vietnam will increase more when the domestic economy recovers, deposit interest rates remain at an attractive level and real estate is at low prices, while the economies in the EU and the US are recovering more slowly than in Vietnam.

With the above factors, Yuanta believes the period of strong exchange rate fluctuations in the second half of 2022 has ended and the exchange rate in the last six months of 2023 will continue to be stable and fluctuate in a range of +/- 3%, below the SBV’s prescribed range of +/- 5%.

However, Yuanta noted, a number of other factors that may put pressure on the exchange rate should be monitored, such as high inflation in developed countries, the reopening of China and the Fed’s longer-than-expected interest rate hike.

Sharing the same view, finance expert Dr. Can Van Luc said as the dollar devaluates and the US economy is forecast to have lower growth, it is likely that the Fed will not continue to raise interest rates until the end of this year, and other currencies, including the Vietnamese Dong, will appreciate again.

Luc predicted the USD/VND exchange rate for the whole of 2023 will be stable. /.

Source: Vietnam News Agency

Posted on

K-Pop phenomenon to storm Hanoi for two nights

Black Pink, the Republic of Korea’s girl group phenomenon, is storming Hanoi at My Dinh stadium for two nights on July 29 and 30.

The announcement was unveiled on their fanpage and official website. Tickets will be up for sale on July 7 at ticketbox.vn.

“Born Pink World Tour” is the ongoing second worldwide concert tour by the group in support of their second album “Born Pink”.

The group kicked off its tour in Seoul in October 2022, and since then it has head to North America, Europe and Asia.

According to statistic of Touring Data, Black Pink’s “Born Pink World Tour” became the highest-grossing tour by a female group in history, surpassing legendary British girl groups Spice Girls’ Spice World -2019 Tour which made 78.2 million USD over 13 sold-out shows.

Meanwhile, the Born Pink tour has made 78.5 million USD over 26 shows with 366,000 tickets and the tour has not yet finished.

The girl group is formed by YG Entertainment, consisting of four members Jisoo, Jennie, Rosé, and Lisa. The group debuted in August 2016 with their single album Square One.

Blackpink has broken numerous online records throughout their career. Their music video for “Ddu-Du Ddu-Du” was the first by a RoK group to surpass 1 billion views and is currently the most-viewed by a RoK group on YouTube.

Blackpink’s music videos for “Kill This Love” (2019) and “How You Like That” (2020) each set records for the most-viewed music video within the first 24 hours of release, with the latter breaking three and setting two Guinness World Records./.

Source: Vietnam News Agency

Posted on

Phu Tho posts strong economic growth in H1

The northern province of Phu Tho has risen to the third position among the northern midland and mountainous localities in economic growth speed, heard a recent meeting of the provincial Party Committee’s Standing Board to review the province’s socio-economic performance in the first half of the year and sketch out plan for the rest of 2023.

According to the provincial People’s Committee, despite difficulties in the domestic and international situation, in the first six months of this year, Phu Tho still posted high economic growth at 7.22%, ranking third among the 14 localities in the region and 16th out of the 63 cities and provinces nationwide.

In the first six months of this year, its industry sector expanded 10.11%, entering the top 10 localities of the nation in the field.

In the period, the locality completed 12 out of the 16 targets and exceeded the budget estimate assigned by the provincial People’s Council. The majority of public invested projects have been implemented with good progress, with the distribution level of public investment higher than the country’s average.

The provincial People’s Committee attributed the results to the province’s efforts to make breakthroughs in improving the local business environment right from the beginning of the year.

In the first half of the year, the locality saw 102 new and expanded projects. It has completed dossiers on the province’s master planning for the 2021-2030 period with a vision to 2050 to submit to the Prime Minister, while finalising dossiers on planning of Viet Tri city.

Alongside, the province has received 4.5 trillion VND (191.24 million USD) of State budget and allocated 4.22 trillion VND, or 93.7% of the plan, to 342 projects.

As of May 31, the disbursement rate of public investment capital was estimated at 37% of the assigned plan, higher than the national average.

Meanwhile, socio-cultural activities have been strengthened, and the administrative reform sped up and social security and order ensured.

Bui Minh Chau, Secretary of the provincial Party Committee, said that 2023 is an important year in the implementation of Phu Tho’s socio-economic development plan in the 2021-2025 period. In the time to come, Phu Tho will focus on improving the local investment and business environment and mobilising resources for development.

At the same time, it will review all the projects with investment policy approved by the provincial Party Committee’s Standing Board, evaluating their feasibility and making suitable adjustments, he said.

The provincial leader underlined that Phu Tho will roll out measures to remove difficulties facing businesses and investors, prioritising domestic and local businesses.

Regarding land management activities, Chau asked the provincial Department of Natural Resources and Environment to review all activities of land allocation, land auction, and land use right conversion in the province over the years, ensuring that they are implemented in compliance with regulations, and resolutely handling violations if there is any.

Alongside, the locality will review the real estate facilities that have been handed over from the separation and merger of local administrative units. In the field of security and defence, the provincial leader requested local police to stay close to local residents and maintain control over the situation, thus settling all arising problems in a timely manner.

With these solutions, Phu Tho is striving to maintain an economic growth rate of at least 7.5% and per capita GRDP of 63 million VND, along with total social investment capital of 43.5 trillion VND. The locality also aims for a total state budget collection of 6.1 trillion VND. The province expects an urbanisation rate of at least 19.6%, together with 71% in the rate of trained and vocational workers. Phu Tho will also work to reduce the rate of poor households by 0.5%./.

Source: Vietnam News Agency

Posted on

Vietnam to host International Federation of Freight Forwarders Association annual meeting in July

The Vietnam Logistics Business Association (VLA) will host the 2023 Asia-Pacific Regional Annual Meeting of the International Federation of Freight Forwarders Associations (FIATA) and the mid-year meeting of the ASEAN Freight Forwarders Association (AFFA) in the central city of Da Nang from July 13 to 15.

The event provides opportunities for Vietnamese logistics and export companies to meet and exchange experiences with world partners in the development of logistics services in the context of the Fourth Industrial Revolution.

About 250 representatives of logistics service companies are expected to attend the FIATA conference, opening up chances for setting up connections between Vietnam and countries around the world in fields such as aviation, catering, hospitality and tourism.

According to a VLA representative, during and after this event, there is good prospect of the conclusion of cooperative agreements between Vietnamese companies and members of logistics associations in the region and the world.

A business-to-business (B2B) programme will be held within the framework of the conference, enabling Vietnamese companies to directly contact foreign partners, and increase exports to international markets./.

Source: Vietnam News Agency